Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen Inc. (Nasdaq: XGN), a leading autoimmune testing provider, has announced its participation in three upcoming investor conferences in early 2025:
1. BTIG at Snowbird Conference on February 11, 2025, at the Cliff Lodge in Snowbird, UT, featuring one-on-one investor meetings.
2. TD Cowen's 45th Annual Health Care Conference on March 5, 2025, at the Marriott Copley Place in Boston, MA, where President and CEO John Aballi and CFO Jeff Black will participate in a fireside chat at 1:10 p.m. EST, along with one-on-one investor meetings.
3. 5th Annual KeyBanc Capital Markets Healthcare Forum on March 18, 2025, featuring a virtual fireside chat and one-on-one investor meetings.
Investors can find more information and fireside chat links in the Events section of Exagen's website.
Exagen Inc. (Nasdaq: XGN), un fornitore leader nel settore dei test autoimmune, ha annunciato la sua partecipazione a tre prossimi conferenze per investitori all'inizio del 2025:
1. BTIG al Snowbird Conference l'11 febbraio 2025, presso il Cliff Lodge a Snowbird, UT, con incontri individuali con gli investitori.
2. 45° Annual Health Care Conference di TD Cowen il 5 marzo 2025, presso il Marriott Copley Place a Boston, MA, dove il Presidente e CEO John Aballi e il CFO Jeff Black parteciperanno a una chiacchierata informale alle 13:10 EST, insieme a incontri individuali con gli investitori.
3. 5° Annual KeyBanc Capital Markets Healthcare Forum il 18 marzo 2025, con una chiacchierata informale virtuale e incontri individuali con gli investitori.
Gli investitori possono trovare ulteriori informazioni e i link per le chiacchierate informali nella sezione Eventi del sito web di Exagen.
Exagen Inc. (Nasdaq: XGN), un proveedor líder en pruebas autoinmunes, ha anunciado su participación en tres próximas conferencias para inversores a principios de 2025:
1. BTIG en la Conferencia Snowbird el 11 de febrero de 2025, en el Cliff Lodge en Snowbird, UT, con reuniones individuales con inversores.
2. 45ª Conferencia Anual de Salud de TD Cowen el 5 de marzo de 2025, en el Marriott Copley Place en Boston, MA, donde el Presidente y CEO John Aballi y el CFO Jeff Black participarán en una charla informal a la 1:10 p.m. EST, junto con reuniones individuales con inversores.
3. 5ª Conferencia Anual de KeyBanc Capital Markets sobre Salud el 18 de marzo de 2025, con una charla informal virtual y reuniones individuales con inversores.
Los inversores pueden encontrar más información y enlaces a las charlas informales en la sección de Eventos del sitio web de Exagen.
엑사젠 Inc. (Nasdaq: XGN), 자가면역 검사 분야의 선두 업체가 2025년 초에 있을 3개의 투자자 회의에 참여한다고 발표했습니다:
1. BTIG 스노우버드 컨퍼런스가 2025년 2월 11일, 유타주 스노우버드의 클리프 로지에서 개최되며, 투자자와의 1:1 미팅이 예정되어 있습니다.
2. TD 카우언의 제45회 연례 의료 회의가 2025년 3월 5일, 매리엇 코플리 플레이스에서 개최되며, 존 아발리 CEO와 제프 블랙 CFO가 오후 1시 10분 EST에 진행되는 비공식 대담에 참여하고, 1:1 투자자 미팅도 예정되어 있습니다.
3. 제5회 키뱅크 캐피탈 마켓 헬스케어 포럼이 2025년 3월 18일에 진행되며, 가상 비공식 대담과 1:1 투자자 미팅이 포함됩니다.
투자자들은 엑사젠 웹사이트의 이벤트 섹션에서 추가 정보와 대담 링크를 찾을 수 있습니다.
Exagen Inc. (Nasdaq: XGN), un fournisseur leader dans le domaine des tests auto-immuns, a annoncé sa participation à trois prochaines conférences pour investisseurs début 2025 :
1. BTIG à la Conférence Snowbird le 11 février 2025, au Cliff Lodge à Snowbird, UT, avec des réunions individuelles avec des investisseurs.
2. 45ème Conférence Annuelle de Santé de TD Cowen le 5 mars 2025, au Marriott Copley Place à Boston, MA, où le Président et CEO John Aballi et le CFO Jeff Black participeront à une discussion informelle à 13h10 EST, ainsi qu'à des réunions individuelles avec des investisseurs.
3. 5ème Forum Annuel sur la Santé de KeyBanc Capital Markets le 18 mars 2025, avec une discussion informelle virtuelle et des réunions individuelles avec des investisseurs.
Les investisseurs peuvent trouver plus d'informations et des liens vers les discussions informelles dans la section Événements du site Web d'Exagen.
Exagen Inc. (Nasdaq: XGN), ein führender Anbieter von Autoimmun-Tests, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen Anfang 2025 angekündigt:
1. BTIG auf der Snowbird-Konferenz am 11. Februar 2025 im Cliff Lodge in Snowbird, UT, mit persönlichen Investorenmeetings.
2. 45. jährliche Gesundheitskonferenz von TD Cowen am 5. März 2025 im Marriott Copley Place in Boston, MA, wo Präsident und CEO John Aballi und CFO Jeff Black um 13:10 Uhr EST an einem informellen Gespräch teilnehmen, zusätzlich zu persönlichen Investorenmeetings.
3. 5. jährliches KeyBanc Capital Markets Healthcare Forum am 18. März 2025, mit einer virtuellen informellen Gesprächsrunde und persönlichen Investorenmeetings.
Investoren finden weitere Informationen und Links zu den informellen Gesprächen im Bereich Veranstaltungen der Website von Exagen.
- None.
- None.
CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences:
BTIG at Snowbird: MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Management will participate in one-on-one investor meetings on Tuesday, February 11ᵗʰ, 2025, at the Cliff Lodge located in Snowbird, UT.
TD Cowen’s 45ᵗʰ Annual Health Care Conference
John Aballi, President and CEO and Jeff Black, CFO, will participate in a fireside chat at 1:10 p.m. EST on Wednesday, March 5ᵗʰ, 2025, at the Marriott Copley Place in Boston, MA. Management will also participate in one-on-one investor meetings.
5ᵗʰ Annual KeyBanc Capital Markets Healthcare Forum
Management will participate virtually in a fireside chat at a time to be determined and one-on-one investor meetings on Tuesday, March 18ᵗʰ, 2025.
Please check the Events section of the Investors page on Exagen.com for more information and links to the fireside chats.
About Exagen
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, please visit Exagen.com or follow @ExagenInc on X (formerly known as Twitter).
Exagen Inc.
Ryan Douglas
IR@exagen.com
760.560.1525
FAQ
What investor conferences will Exagen (XGN) attend in early 2025?
When is Exagen's (XGN) fireside chat at TD Cowen's Healthcare Conference?
Which Exagen (XGN) executives will present at TD Cowen's Conference?
Where can investors find links to Exagen's (XGN) conference presentations?
Which of Exagen's (XGN) 2025 investor conferences will be virtual?
